

POLICY AND STRATEGY, DOCUMENT

Influenza vaccines and eligible cohorts for the 2024 to 2025 season (WHC/2023/047)

Letter to health professionals about the 2024 to 2025 national influenza vaccination programme.

First published: 21 December 2023

Last updated: 12 June 2024

Contents

Information

Footnotes

Issue date:

21 December 2023. (Revised June 2024)

Status:

Compliance/Action

Category:

Public health

Title:

Influenza vaccines and eligible cohorts for the 2024 to 2025 season

Date of expiry / review:

Not applicable

For action by:

Chief executives, Health Boards/Trusts
Immunisation leads, Health Boards/Trusts
Immunisation coordinators, Health Boards
Vaccination operational leads, Health Boards/Trusts
Medical directors, Health Boards/Trusts
Directors of Primary Care, Health Boards/Trusts

Nurse executive directors, Health Boards/Trusts

Directors of Therapies and Health Sciences, Health Boards/Trusts

Chief pharmacists, Health Boards/Trusts

Directors of Public Health, Health Boards/Trusts

Directors of maternity services, Health Boards

Directors of Workforce and Organisational Development, Health Boards/Trusts

Executive Director of Public Health, Public Health Wales

Nurse director, Public Health Wales

Head of Vaccine Preventable Disease Programme, Public Health Wales

Director of planning, vaccination programme Wales

General practitioners

Community pharmacists

Digital Health and Care Wales

For information to:

Welsh NHS Partnership Forum

General Practitioner Council, Wales

Royal College of GPs

Royal College of Nursing

Royal College of Midwives

Royal College of Paediatrics and Child Health

British Dental Association

Royal Pharmaceutical Society

Community Pharmacy Wales

Care Inspectorate Wales

Chief Executive, Welsh Local Government Association for onward issue to:

Directors of Social Services, Local authorities

Directors of Public Protection, Local authorities

Directors of Education, Local authorities

Social Care Wales

Health Education and Improvement Wales

Action required by:

N/A.

Sender:

Dr Frank Atherton, Chief Medical Officer / Medical Director NHS Wales

Welsh Government contact:

Vaccination Division, Welsh Government, Cathays Park, Cardiff CF10 3NQ

Email: wg.vaccinationsprogrammeteam@gov.wales

Enclosure(s):

None

Information

Dear Colleagues,

This revised Welsh Health Circular replaces the version issued on 19 December 2023 and is being published to confirm:

• eligible cohorts for the 2024 to 2025 influenza (flu) season

- reimbursable vaccines for the 2024 to 2025 flu season (including changes made from the previous version of this Welsh Health Circular)
- changes to the start of the 2024 to 2025 adult flu vaccination programme (except for pregnant women)

Eligible cohorts for the influenza (flu) season in 2024 to 2025

The JCVI has not recommended any changes to the eligibility criteria which applied for the 2023 to 2024 programme. Therefore, the groups eligible for a flu vaccine in Wales as part of the routine national flu programme in 2024 to 2025 will be as follows:

- children aged two and three years on 31 August 2024
- school aged children from reception to year 11 (inclusive)
- people aged 6 months to 64 years in a clinical risk group
- people aged 65 years and older (age on 31 March 2025)
- · all adult residents in Welsh prisons
- pregnant women
- · carers of a person whose health or welfare may be at risk if the carer falls ill
- · frontline health and care workers
- people experiencing homelessness
- · household contacts of the immunocompromised

Reimbursable vaccines in 2024 to 2025

Taking into account the vaccines recommended by the JCVI for the 2024 to 2025 flu season, the vaccines eligible for reimbursement in Wales for the different age cohorts will be as follows:

Those aged 65 years and over

- aQIV [footnote 1]
- QIV- HD [footnote 2]
- QIVc where aQIV/QIV-HD is not available [footnote 3]

Those aged 18 to less than 65 years (including pregnant women)

- QIVc
- QIV HD (those aged 60 years and over only)

Children aged 2 to less than 18 years who are contraindicated/ decline LAIV

QIVc

Children aged 6 months to 2 years in risk groups

QIVc

Key:

aQIV - adjuvanted quadrivalent influenza vaccine QIVc - quadrivalent cell culture influenza vaccine QIV-HD - high dose quadrivalent inactivated influenza vaccine

This revised Welsh Health Circular is being issued following a notification from the manufacturer of QIVr - quadrivalent recombinant influenza vaccine - that this product will not be available as expected in the UK for the 2024 to 2025 [footnote]

^{4]}season. Orders for an appropriate alternative should be placed as soon as possible. Vaccination Programme Wales will work closely with health boards to support contractors impacted by this change. General practices, community pharmacies and health boards/trusts should ensure that flu vaccine orders are sufficient to facilitate high uptake.

For the children's programme, live attenuated influenza vaccine (LAIV) is the recommended vaccine for eligible children aged 2-17 years of age, unless contraindicated or declined due to gelatine content. Where there is a clinically determined need for a less invasive procedure, such as for some adults with a learning disability, the use of LAIV may be considered a reasonable adjustment (see here for more details on gov.uk's website). LAIV is supplied centrally and will be available to order through ImmForm.

Changes to the start of the 2024 to 2025 vaccination programme

JCVI has recently advised that the evidence on vaccination effectiveness supports the case for moving the start of the adult flu vaccination programme to early October. The committee has recommended there should be no change to the start of the children's programme as evidence shows early vaccination of children provides the best protection against transmission.

It has also recommended pregnant women should continue to be vaccinated in September, if delaying until October would mean they risk missing out on vaccination.

In the light of the committee's advice, we will adopt a phased approach to the commencement of the flu vaccination programme in 2024 as follows:

• During September, general practices and health boards should concentrate their efforts on maximising uptake in the children's programme, both

- amongst school-age children and 2-and 3-year-olds.
- The main adult vaccination programme should begin at the start of October and be delivered at pace with an expectation that all eligible patients should be offered a vaccination by early December.

Where a Primary Care contractor does not have confidence that it will be possible to vaccinate their entire eligible adult cohort between October and early December, they should inform their health board. In this event, the health board can agree for vaccination to begin in September, rather than risk failing to complete the programme in a timely way.

The flu vaccination programme is a vital element of our winter planning and resilience arrangements. I have been disappointed to see lower than expected uptake in the 2023 to 2024 programme and I hope the details set out above will support colleagues to develop effective plans to ensure the 2024 to 2025 programme is a successful one.

Finally, I would like to offer my sincere thanks for all the hard work that goes into delivering our vaccination programmes, which offer vital protection to eligible citizens and to our health service through the winter months.

Yours sincerely,

Sir Frank Atherton

Chief Medical Officer / Medical Director NHS Wales

Footnotes

[1] aQIV may be offered 'off-label' to those who become 65 years of age before 31 March 2025.

- [2] QIV-HD was not previously available in the UK but its manufacturers have confirmed that it will now be made available for 2024 to 2025.
- [3] Whether a vaccine is 'available' should be a balance of clinical and operational judgement. The potential delay in sourcing the preferred vaccine (due to a temporary or localised shortage or a national batch failure) should be weighed against the protection afforded by the alternative vaccine. Whether the flu virus is circulating or is imminent at the time would be a factor in making this judgement.
- [4] JVCI recommended QIVr for the vaccination of those aged 18 years and over and this product was identified as eligible for reimbursement in the previous version of this Welsh Health Circular.

This document may not be fully accessible.

For more information refer to our accessibility statement.